Skip to Content
MilliporeSigma

Skip To

C3742

Chk2 Inhibitor II hydrate

≥98% (HPLC)

Synonym(s):

2-(4-(4-Chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Size/SKUAvailabilityPrice
5 mg

Available to ship TODAYfromMILWAUKEE

$242.00
$205.70

About This Item

Empirical Formula (Hill Notation):
C20H14ClN3O2 · xH2O
CAS Number:
Molecular Weight:
363.80 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
solid

$205.70

List Price$242.00Save 15%
Web-Only Promotion

Available to ship TODAYDetails


Request a Custom Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Quality Segment

assay

≥98% (HPLC)

form

solid

color

off-white to tan

solubility

DMSO: ≥2 mg/mL (warmed)

originator

Johnson & Johnson

storage temp.

2-8°C

SMILES string

O=C(C1=CC=C2C(N=C(C3=CC=C(OC4=CC=C(Cl)C=C4)C=C3)N2)=C1)N

InChI

1S/C20H14ClN3O2/c21-14-4-8-16(9-5-14)26-15-6-1-12(2-7-15)20-23-17-10-3-13(19(22)25)11-18(17)24-20/h1-11H,(H2,22,25)(H,23,24)

InChI key

UXGJAOIJSROTTN-UHFFFAOYSA-N

Gene Information

human ... CHEK2(11200)

Biochem/physiol Actions

Chk2 Inhibitor II is a checkpoint kinase 2 inhibitor, which controls the p53 response to DNA breaks induced by radiation, leading to apoptosis. Protection of T-cells from apoptosis implies use as an adjuvant for radiation therapy in cancer.
Chk2 Inhibitor II is a checkpoint kinase 2 inhibitor, which controls the p53 response to DNA breaks induced by radiation, leading to apoptosis. Protection of T-cells from apoptosis implies use as an adjuvant for radiation therapy in cancer. IC50 = 15 nM; Ki = 37 nM. Chk2 Inhibitor II shows 1000-fold greater selectivity for the Chk2 serine/threonine kinase than for the Cdk1/B and CK1 kinases (for which IC50 = 12 μM and 17 μM, respectively). Chk2 Inhibitor II weakly inhibits a panel of 31 other kinases (<25% inhibition at a concentration of 10 μM and prevents apoptosis of human CD4+ and CD8+ T-cells subjected to ionizing radiation (EC50 = 3 μM and 7.6 μM, respectively).

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
S7076220486G5793
form

solid

form

solid

form

solid

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥95% (HPLC)

assay

>98% (HPLC)

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: ≥2 mg/mL (warmed)

solubility

DMSO: ≥12 mg/mL

solubility

DMSO: 5 mg/mL

solubility

DMSO: 10 mg/mL, clear

color

off-white to tan

color

white to beige

color

pale yellow

color

white to beige

originator

Johnson & Johnson

originator

GlaxoSmithKline

originator

-

originator

GlaxoSmithKline


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Questions

Reviews

No rating value

Active Filters